ABOUT THE VISTA CLINICAL TRIAL

  • The VISTA clinical trial is studying an investigational (not yet FDA-approved) gene therapy called AGTC-501 for patients with X-linked retinitis pigmentosa (XLRP).
  • Gene therapy is the process of injecting a healthy gene to replace a damaged or mutated one.
  • The investigational gene therapy (AGTC-501) is designed to replace the mutated RPGR gene that causes XLRP.
  • The purpose of the VISTA phase 2/3 clinical trial is to evaluate the safety and effectiveness of AGTC-501 and to determine whether it may help a person with XLRP see better or maintain their current vision.